{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:29:03Z","timestamp":1792114143007,"version":"4.4.0"},"reference-count":30,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To capture patient perceptions about living with myasthenia gravis (MG) with respect to aspirations and ways to improve treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Online patient survey.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Patients recruited by MG patient associations or at MG reference treatment centres.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Adults with physician-diagnosed generalised MG, living in France for \u226512 months, who had received \u22651\u2009MG treatment were eligible. 291 patients opened the questionnaire, 255 were eligible and 246 completed the survey (age range 41\u201367 years; 187\u2009women and 59 men).<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>Primary: free-text response to the question \u2018Living with your disease, what would you like to do that you currently find difficult or impossible to do?\u2019 Secondary: free-text response to the question \u2018What improvements do you think could be made to treatments for MG?\u2019 Themes from replies to these questions were analysed using grounded theory and cluster analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For the disease aspirations question, 617 citations were provided by 238 participants, which were grouped into 45 dimensions and six high-level domains (physical activity, activities of daily living, psychological burden, social activities, work\/school and other). The most frequently cited dimensions were sport (82 citations), greater mobility (56 citations), being less tired (46 citations) and greater endurance (37 citations). Younger age, female gender, recent diagnosis and poorer quality of life were associated with citing more themes. For the treatment amelioration question, 263 citations were provided by 195 participants, which were grouped into 60 dimensions and three high-level domains (medication characteristics, safety and care paradigm). The most cited treatment-related dimensions were fewer side effects (40 citations), fewer daily medication intakes (21 citations) and fewer digestive side effects (20 citations).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These findings could help healthcare professionals to understand and better address patients\u2019 aspirations about living with MG, notably concerning the importance of physical activity, and their expectations for improved treatments.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088813","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T12:25:31Z","timestamp":1733142331000},"page":"e088813","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["SPOON: an observational, cross-sectional study of perceptions and expectations of adults with generalised myasthenia gravis in France"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5282-6707","authenticated-orcid":false,"given":"Jean-Philippe","family":"Camdessanch\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Crochard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Bertocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali\u00e9nor","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Edouard","family":"Villy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"2025010105152386000_14.12.e088813.1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"2025010105152386000_14.12.e088813.2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neurol.2023.09.004","article-title":"Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA)","volume":"180","author":"Salort-Campana","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"2025010105152386000_14.12.e088813.3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025010105152386000_14.12.e088813.4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","article-title":"Fatigue in patients with myasthenia gravis. A systematic review of the literature","volume":"30","author":"Ruiter","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2025010105152386000_14.12.e088813.5","unstructured":"Miserando C . The Spoon Theory, 2003. Available: https:\/\/butyoudontlooksick.com\/articles\/written-by-christine\/the-spoon-theory"},{"key":"2025010105152386000_14.12.e088813.6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.553626","article-title":"Determinants of Quality of Life in Myasthenia Gravis Patients","volume":"11","author":"Szczudlik","year":"2020","journal-title":"Front Neurol"},{"key":"2025010105152386000_14.12.e088813.7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/NRL.0000000000000238","article-title":"Quality of Life of Myasthenia Gravis Patients in Regard to Epidemiological and Clinical Characteristics of the Disease","volume":"24","author":"Stojanov","year":"2019","journal-title":"Neurologist"},{"key":"2025010105152386000_14.12.e088813.8","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00415-020-09767-7","article-title":"Depression in myasthenia gravis: a heterogeneous and intriguing entity","volume":"267","author":"Gavrilov","year":"2020","journal-title":"J Neurol"},{"key":"2025010105152386000_14.12.e088813.9","first-page":"e1382","article-title":"Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study","volume":"97","author":"Petersson","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025010105152386000_14.12.e088813.10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","article-title":"The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis","volume":"10","author":"Law","year":"2021","journal-title":"Neurol Ther"},{"key":"2025010105152386000_14.12.e088813.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068104","article-title":"Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG)","volume":"13","author":"Berrih-Aknin","year":"2023","journal-title":"BMJ Open"},{"key":"2025010105152386000_14.12.e088813.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-066445","article-title":"Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG","volume":"13","author":"Dewilde","year":"2023","journal-title":"BMJ Open"},{"key":"2025010105152386000_14.12.e088813.13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2215-0366(20)30191-7","article-title":"Identifying outcomes for depression that matter to patients, informal caregivers, and health-care professionals: qualitative content analysis of a large international online survey","volume":"7","author":"Chevance","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2025010105152386000_14.12.e088813.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-172X.2006.00543.x"},{"key":"2025010105152386000_14.12.e088813.15","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000000388"},{"key":"2025010105152386000_14.12.e088813.16","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"key":"2025010105152386000_14.12.e088813.17","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology (ECronicon)"},{"key":"2025010105152386000_14.12.e088813.18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318258f744"},{"key":"2025010105152386000_14.12.e088813.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2025010105152386000_14.12.e088813.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023028"},{"key":"2025010105152386000_14.12.e088813.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.10.001"},{"key":"2025010105152386000_14.12.e088813.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-019-0132-y","article-title":"Patients\u2019 views of wearable devices and AI in healthcare: findings from the ComPaRe e-cohort","volume":"2","author":"Tran","year":"2019","journal-title":"NPJ Digit Med"},{"key":"2025010105152386000_14.12.e088813.23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jdv.17742","article-title":"Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo e-cohort","volume":"36","author":"Shourick","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025010105152386000_14.12.e088813.24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/cid\/ciab352","article-title":"Development and Validation of the Long Coronavirus Disease (COVID) Symptom and Impact Tools: A Set of Patient-Reported Instruments Constructed From Patients\u2019 Lived Experience","volume":"74","author":"Tran","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025010105152386000_14.12.e088813.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120268","article-title":"The humanistic burden of myasthenia gravis: A systematic literature review","volume":"437","author":"Gelinas","year":"2022","journal-title":"J Neurol Sci"},{"key":"2025010105152386000_14.12.e088813.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol"},{"key":"2025010105152386000_14.12.e088813.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2011.01.005"},{"key":"2025010105152386000_14.12.e088813.28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1348\/014466501163904","article-title":"Normative data for the HADS from a large non\u2010clinical sample","volume":"40","author":"Crawford","year":"2001","journal-title":"British J Clinic Psychol"},{"key":"2025010105152386000_14.12.e088813.29","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient\u2019s perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"2025010105152386000_14.12.e088813.30","first-page":"e1617","article-title":"Patient-acceptable symptom states in myasthenia gravis","volume":"95","author":"Mendoza","year":"2020","journal-title":"Neurology (ECronicon)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T13:15:48Z","timestamp":1735737348000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,2]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bmjopen-2024-088813"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088813","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}